[Secondary and tertiary prevention of @entity56 in XXXX ].

@entity1 @entity2023 @entity565 @entity566 @entity56 @entity1576
@entity565 is a disease of the lung epithelial barrier, most often associated with @entity566 in @entity1 . @entity565 and @entity566 are two distinct diseases, but the phenotypic expression of @entity565 depends on atopic status. A better definition of phenotypes of @entity565 would result in better targeting of prevention and treatment modalities. Secondary prevention aims to prevent the onset of @entity565 and the acquisition of new sensitizations in sensitized @entity1 . Studies concerning allergen avoidance are insufficient to reach a definitive conclusion and antihistamines have not been shown to be effective. The results for specific immunotherapy suggest a benefit to prevent transition from @entity2023 to @entity565 and the onset of new sensitizations. Tertiary prevention aims to reduce symptoms in @entity1 with an existing @entity56 diagnosis. The avoidance of known @entity1576 will only be effective in combination with management of the whole environment. Specific immunotherapy has a real place, in combination with background therapy. It should be used according to guidelines in appropriately treated @entity1 .
